JAHA:降压药物不依从性的全球负担、地区差异、趋势和健康结局

2022-09-04 MedSci原创 MedSci原创

虽然在全球范围内检测到降压药物不依从性的高发生率,但在中低收入和非西方国家检测到更高的发生率。

降压药物不依从是导致血压控制不佳,它是导致全球心血管疾病和死亡率的主要原因。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员通过对2010年至2020年期间的数据进行了系统评价和荟萃分析,调查了降压药物不依从性全球流行病学数据、地区差异和趋势。研究人员从多个医学数据库和临床试验网站上检索了文章,并纳入了报告降压药物不依从性患者比例的观察性研究。

此外,研究人员提取了降压药物不依从性导致的健康结局、出版年份、首次招募年份、降压药物不依从性的患者比例。两位作者筛选了摘要和全文,根据收入水平和地点对国家进行了分类,并提取数据。研究人员采用患病率关键评估工具用于对纳入的研究进行评分,并使用固定效应模型进行患病率荟萃分析,以及通过Meta回归分析患病率趋势。关于不依从性对健康结局的影响的证据的确定性根据建议、评估、发展和评估的分级进行评级。

该分析共纳入了161项研究。受不同检测方法的影响,降压药物不依从性的全球患病率为27%至40%。不依从性在低收入和中等收入国家比在高收入国家更为普遍,在非西方国家比在西方国家更为普遍。2010年至2020年期间未检测到患病率的显著上升趋势。降压药物依从性差的患者血压控制不佳、高血压并发症、全因住院和全因死亡率升高。

虽然在全球范围内检测到降压药物不依从性的高发生率,但在中低收入和非西方国家检测到更高的发生率。迫切需要干预,尤其是在这些地区。目前的证据受到高度异质性的限制。

原始出处:

Eric K. P. Lee.et al.Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta‐Analysis Involving 27 Million Patients.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.122.026582

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054224, encodeId=f83420542246c, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Aug 03 07:59:54 CST 2023, time=2023-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268895, encodeId=769a12688952d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292176, encodeId=e23e12921e6dd, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319370, encodeId=807c13193e0d6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2054224, encodeId=f83420542246c, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Aug 03 07:59:54 CST 2023, time=2023-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268895, encodeId=769a12688952d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292176, encodeId=e23e12921e6dd, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319370, encodeId=807c13193e0d6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=)]
    2022-09-06 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=2054224, encodeId=f83420542246c, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Aug 03 07:59:54 CST 2023, time=2023-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268895, encodeId=769a12688952d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292176, encodeId=e23e12921e6dd, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319370, encodeId=807c13193e0d6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2054224, encodeId=f83420542246c, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Aug 03 07:59:54 CST 2023, time=2023-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268895, encodeId=769a12688952d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292176, encodeId=e23e12921e6dd, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319370, encodeId=807c13193e0d6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Sep 06 08:59:54 CST 2022, time=2022-09-06, status=1, ipAttribution=)]
    2022-09-06 fyxzlh

相关资讯

Am J Resp Crit Care:婴儿呼吸道微生物群的成熟、环境驱动因素和健康结局之间的分析!

该研究结果表明,环境驱动因素影响微生物群落的发展,从而抵抗RTIs的发展。这支持了微生物群成为早期生命环境危险因素与生命第一年的RTI易感性之间介导者的观点。

J Manag Care Spec Pharm:教育性邮件对糖尿病患者健康结局的价值存疑

发表在《J Manag Care Spec Pharm》的一项由美国科学家进行的研究考察了个性化治疗和胰岛素作为优化糖尿病治疗手段的作用。

JAMA Health Forum:患者导向付费模式是否与专业护理机构的患者康复治疗和健康结果相关?

PDPM的实施与治疗使用减少相关,而没有改变随后的住院风险和出院功能评分。

J Hypertens:宫内暴露于抗高血压药物与新生儿和儿童健康结局的相关性分析!

目前这项系统评价的结果表明缺乏相关的已发表的高质量研究。少数研究表明可能增加儿童不良健康结局的风险;然而,大多数已发表的研究都存在方法论上的缺点和/或缺乏统计效能,因此,无法得出任何确切的结论。